Premature ejaculation is one of the most common forms of sexual dysfunction in men throughout the world with prevalence of 20-30% in men of all ages. In the past, premature ejaculation was assumed to have a psychological basis but new neurophysiologic research strongly suggests abnormal metabolism in areas of the brain where sexual responses are integrated. Current treatment of premature ejaculation can be psychological and/or pharmacological. Medical therapy such as lidocaine, Tramadol and SRIs used prior to sexual intercourse has showed improvements in intercourse satisfaction. In particular, a new short acting SRI called Dapoxetine, which is being developed specifically for premature ejaculation, has demonstrated a significant increase in intravaginal ejaculatory latency time from less than 1 minute to over 3 minutes.